Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Idaho Sci-Tech Network.
Press releases published on June 6, 2025

Huize Holding Limited Reports First Quarter 2025 Unaudited Financial Results
SHENZHEN, China, June 06, 2025 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance carriers and distribution partners digitally through data- …

QuantaSing Announces Unaudited Financial Results for the Third Quarter of Fiscal Year 2025
BEIJING, June 06, 2025 (GLOBE NEWSWIRE) -- QuantaSing Group Limited (NASDAQ: QSG) (“QuantaSing” or the “Company”), a leading lifestyle solution provider, today announced its unaudited financial results for the third quarter of the fiscal year ending June …

Burning Rock Reports First Quarter 2025 Financial Results
GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today …

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. …

浩鼎自创ADC平台GlycOBI® 首宗技术合作案 携手美国TegMine开发ADC
台湾, June 06, 2025 (GLOBE NEWSWIRE) -- 浩鼎生技(以下简称「浩鼎」)(4174.TWO)今(06/06)宣布,与美国TegMine Therapeutics, Inc.(以下简称「TegMine」)签署ADC研发服务合约(Master Services Agreement, MSA);TegMine 是一家总部位于美国旧金山的生物制药公司,专注于开发针对癌症相关糖蛋白的创新抗体疗法。浩鼎则致力于开发抗癌新药及聚焦研发次世代抗体药物复合体(ADCs)。 根据合约,浩鼎将与 …

浩鼎自創ADC平台GlycOBI® 首宗技術合作案 攜手美國TegMine開發ADC
台灣, June 06, 2025 (GLOBE NEWSWIRE) -- 浩鼎生技(以下簡稱「浩鼎」)(4174.TWO)今(06/06)宣布,與美國TegMine Therapeutics, Inc.(以下簡稱「TegMine」)簽署ADC研發服務合約(Master Services Agreement, MSA);TegMine 是一家總部位於美國舊金山的生物製藥公司,專注於開發針對癌症相關醣蛋白的創新抗體療法。浩鼎則致力於開發抗癌新藥及聚焦研發次世代抗體藥物複合體(ADCs)。 根據合約,浩鼎將與 …

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for …

GPUNET Completes $4M Buyback from Early Investors, Reinforcing Long-Term Growth
Dubai, UAE, June 05, 2025 (GLOBE NEWSWIRE) -- GPUNET has successfully completed a $4 million buyback of $GPU tokens from its early Series A investors, delivering 2-3x returns to investors who backed the project in 2022 and 2023. All buybacks were executed …

ZenaTech lanza Drones como un Servicio (DaaS) para agencias de defensa y gobierno de EE. UU. con nuevas alianzas
VANCOUVER, Columbia Británica, June 05, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), una empresa de tecnología especializada en drones con inteligencia artificial (IA), Drones como un Servicio (DaaS), …